Trial
NCT02041091
A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Lupus Erythematosus, Systemic
Intervention
Tabalumab Auto-Injector
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-06-15